|1 to 10 of 619||Next||Last|
Congress may now be in recess, but tax reform remains the talk of the town as congressional Republicans grow increasingly anxious to see what the Trump administration puts forward in its forthcoming tax plan.
The Food and Drug Administration (FDA) Reauthorization Act of 2017 renews FDA's authority to collect user fees from the makers of prescription brand drugs, medical devices, generic drugs and biosimilars, and several vital programs at the FDA which are important to America’s seniors.
President Donald Trump's FY 2108 budget blueprint calling for the elimination of the Corporation for National and Community Service prompts proponents to tout bipartisan support for the agency, as well as hearings highlighting its funding abuses by opponents.
In a major turn of events last week, House Republicans ended up pulling the proposed American Health Care Act of 2017 (HR 1628) which would have repealed the Affordable Care Act (ACA or Obamacare) from consideration on the House floor. This outcome complicates plans to tackle comprehensive tax reform this spring, an action that was intended to follow the successful "repeal and replace" deal for the ACA.
The House Energy and Commerce subcommittee on health has scheduled a hearing for Wednesday, March 22, at 10:15 a.m. ET, in room 2322 of the Rayburn House Office Building, Washington, DC. The hearing is titled, “Examining FDA’s Prescription Drug User Fee Program.”
The Senate voted 55-43 on Monday (March 13) to approve Seema Verma’s appointment as administrator of the Centers for Medicare and Medicaid Services. Verma's confirmation comes as congressional Republicans continue pressing to repeal and replace Obamacare, an overhaul that would require considerable involvement from CMS. The health care bill making its way through the House currently plans to eliminate Medicaid expansion after 2020.
This week, House Republicans released the text of legislation that will "repeal and replace" the Affordable Care Act (often referred to as the ACA or Obamacare). The bill’s release was met with both praise and criticism.
Dubbed the American Health Care Act, the 123-page bill surfaced Monday night, with House Republican leaders promising to begin marking it up as early as Wednesday (March 8) in two committees, even though very few House Republicans had a chance to review the measure prior to its release. Indeed, the Congressional Budget Office hasn’t yet issued its assessment of the bill's cost and impact on coverage levels.
The House Energy and Commerce subcommittee on Health, chaired by Rep. Michael Burgess, M.D. (R-TX), held a hearing Thursday examining the Generic Drug User Fee Amendments of 2012 (GDUFA) and the Biosimilar User Fee Act of 2012 (BsUFA), both of which expire in September and must be reauthorized for the Fiscal Years 2018-2022. Also discussed during the hearing was legislation introduced by Reps. Gus Bilirakis (R-FL) and Kurt Schrader (D-OR) -- HR 749, the proposed Lower Costs Through Competition Act.
According to the Government Accountability Office, financial fraud targeting older Americans costs an estimated $2.9 billion annually. This bipartisan legislation would put in place a commonsense plan to protect older Americans from financial exploitation by providing support to regulators, financial institutions, and legal organizations to educate their employees to identify and prevent financial exploitation of older Americans.
|1 to 10 of 619||Next||Last|